You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameArtemether
Accession NumberDB06697
TypeSmall Molecule
GroupsApproved
DescriptionArtemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
Structure
Thumb
Synonyms
(1R,4S,5R,8S,9R,10S,12R,13R)-10-Methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane
10-Methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
Artemetero
Artemetherum
Artemisininelactol methyl ether
beta-Artemether
beta-Dihydroartemisinin methyl ether
Dihydroartemisinin methyl ether
Dihydroqinghaosu methyl ether
Methyl-dihydroartemisinine
SM-224
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
CoartemNovartis Pharmaceuticals Corporation
SaltsNot Available
Categories
UNIIC7D6T3H22J
CAS number71963-77-4
WeightAverage: 298.3746
Monoisotopic: 298.178023942
Chemical FormulaC16H26O5
InChI KeyInChIKey=SXYIRMFQILZOAM-HVNFFKDJSA-N
InChI
InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1
IUPAC Name
(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0⁴,¹³.0⁸,¹³]hexadecane
SMILES
[H][C@@]12CC[C@@H](C)[C@]3([H])CC[C@@]4(C)OO[C@@]13[C@]([H])(O[[email protected]](OC)[C@@H]2C)O4
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as artemisinins. These are sesquiterpenoids originally isolated from the herb Artemisia annua. Their structure is based on artemisinin, a tetracyclic compound that contains a 1,2-dioxepane fused to an octahydrobenzopyran moiety. The internal peroxide bridge is believed to be a key to the mode of action of artemisinins.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassSesquiterpenoids
Direct ParentArtemisinins
Alternative Parents
Substituents
  • Artemisinin skeleton
  • Oxepane
  • 1,2,4-trioxane
  • Oxane
  • Dialkyl peroxide
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationArtemether and lumefantrine combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
PharmacodynamicsIn the body, artemether is metabolized into the active metabolite metabolite dihydroartemisinin. The drug works against the erythrocytic stages of P. falciparum by inhibiting nucleic acid and protein synthesis. Artemether is administered in combination with lumefantrine for improved efficacy. Artemether has a rapid onset of action and is rapidly cleared from the body. It is thought that artemether provides rapid symptomatic relief by reducing the number of malarial parasites. Lumefantrine has a much longer half life and is believed to clear residual parasites.
Mechanism of actionInvolves an interaction with ferriprotoporphyrin IX (“heme”), or ferrous ions, in the acidic parasite food vacuole, which results in the generation of cytotoxic radical species. The generally accepted mechanism of action of peroxide antimalarials involves interaction of the peroxide-containing drug with heme, a hemoglobin degradation byproduct, derived from proteolysis of hemoglobin. This interaction is believed to result in the formation of a range of potentially toxic oxygen and carbon-centered radicals.
Related Articles
AbsorptionFood increases absorption.
Volume of distributionNot Available
Protein bindingArtemether and lumefantrine are both highly bound to human serum proteins in vitro (95.4% and 99.7%, respectively). Dihydroartemisinin is also bound to human serum proteins (47% to 76%).
Metabolism

Rapidly metablized to its active metabolite, dihydroartemisinin.

SubstrateEnzymesProduct
Artemether
Dihydroartemisinin (DHA)Details
Artemether
Not Available
9,10-dihydrodeoxy-artemsininDetails
Artemether
Not Available
Alpha-dihydroartemisininDetails
Artemether
Not Available
DeoxyartemsininDetails
Artemether
Not Available
Deoxydihydro-artemisininDetails
Route of eliminationNot Available
Half lifeArtemether, 1.6 +/- 0.7 and 2.2 +/- 1.9 hr; Dihydroartemisinin, 1.6 +/- 0.6 and 2.2 +/- 1.5 hr
ClearanceNot Available
ToxicityAnimal studies on acute toxicity show that the LD50 of Artemether in mice is a single i.g. administration of 895mg/kg and a single i.m. injection of 296mg/kg dose; in rats, the LD50 is a single i.m. injection of 597mg/kg dose.
Affected organisms
  • Plasmodium
Pathways
PathwayCategorySMPDB ID
Artemether Metabolism PathwayDrug metabolismSMP00651
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9012
Blood Brain Barrier+0.9393
Caco-2 permeable+0.7876
P-glycoprotein substrateSubstrate0.6031
P-glycoprotein inhibitor IInhibitor0.8918
P-glycoprotein inhibitor IINon-inhibitor0.7056
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8665
CYP450 2D6 substrateSubstrate0.5341
CYP450 3A4 substrateSubstrate0.7023
CYP450 1A2 substrateInhibitor0.6829
CYP450 2C9 inhibitorNon-inhibitor0.9413
CYP450 2D6 inhibitorNon-inhibitor0.9474
CYP450 2C19 inhibitorNon-inhibitor0.8733
CYP450 3A4 inhibitorNon-inhibitor0.9434
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9672
Ames testNon AMES toxic0.7285
CarcinogenicityNon-carcinogens0.9179
BiodegradationNot ready biodegradable0.9956
Rat acute toxicity2.2114 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9502
hERG inhibition (predictor II)Non-inhibitor0.7601
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point86-90Not Available
water solubilityInsoluble # http://www.rxlist.com/coartem-drug.htm
logP3.53AVERY,MA ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.457 mg/mLALOGPS
logP3.02ALOGPS
logP3.48ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)-3.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area46.15 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity74.66 m3·mol-1ChemAxon
Polarizability32.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.86 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference
  1. Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6. Pubmed
General References
  1. Makanga M, Krudsood S: The clinical efficacy of artemether/lumefantrine (Coartem). Malar J. 2009 Oct 12;8 Suppl 1:S5. doi: 10.1186/1475-2875-8-S1-S5. [PubMed:19818172 ]
  2. Mutabingwa TK, Adam I: Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? Expert Rev Anti Infect Ther. 2013 Feb;11(2):125-35. doi: 10.1586/eri.12.169. [PubMed:23409819 ]
  3. Haynes RK, Vonwiller SC: Extraction of artemisinin and artemisinic acid: preparation of artemether and new analogues. Trans R Soc Trop Med Hyg. 1994 Jun;88 Suppl 1:S23-6. [PubMed:8053018 ]
External Links
ATC CodesP01BF01P01BE02
AHFS Codes
  • 8:30.08
PDB EntriesNot Available
FDA labelDownload (1.73 MB)
MSDSDownload (566 KB)
Interactions
Drug Interactions
Drug
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Artemether.
5'-Deoxy-5'-MethylthioadenosineThe risk or severity of adverse effects can be increased when Artemether is combined with 5'-Deoxy-5'-Methylthioadenosine.
AbirateroneThe metabolism of Artemether can be decreased when combined with Abiraterone.
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Artemether.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Artemether.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Artemether.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Artemether.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Artemether.
AlimemazineThe serum concentration of Alimemazine can be increased when it is combined with Artemether.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Artemether.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Artemether.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Artemether.
AmantadineAmantadine may increase the QTc-prolonging activities of Artemether.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Artemether.
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Artemether.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Artemether.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Artemether.
AmlodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Amlodipine.
AmodiaquineThe risk or severity of adverse effects can be increased when Artemether is combined with Amodiaquine.
AmodiaquineThe serum concentration of Artemether can be decreased when it is combined with Amodiaquine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Artemether.
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Artemether.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Artemether.
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Artemether.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Artemether.
AmrinoneThe risk or severity of adverse effects can be increased when Artemether is combined with Amrinone.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Artemether.
AnagrelideAnagrelide may increase the QTc-prolonging activities of Artemether.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Artemether.
ApomorphineApomorphine may increase the QTc-prolonging activities of Artemether.
AprepitantThe serum concentration of Artemether can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Artemether.
ArformoterolArformoterol may increase the QTc-prolonging activities of Artemether.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Artemether.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Artemether.
AripiprazoleThe metabolism of Aripiprazole can be decreased when combined with Artemether.
ArmodafinilThe metabolism of Artemether can be decreased when combined with Armodafinil.
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Artemether.
ArtesunateThe risk or severity of adverse effects can be increased when Artemether is combined with Artesunate.
AsenapineAsenapine may increase the QTc-prolonging activities of Artemether.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Artemether.
AtazanavirThe metabolism of Artemether can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Artemether can be decreased when combined with Atomoxetine.
AtovaquoneThe risk or severity of adverse effects can be increased when Artemether is combined with Atovaquone.
AzelastineThe metabolism of Azelastine can be decreased when combined with Artemether.
AzelnidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Azelnidipine.
AzimilideThe risk or severity of adverse effects can be increased when Artemether is combined with Azimilide.
AzithromycinAzithromycin may increase the QTc-prolonging activities of Artemether.
BarnidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Barnidipine.
BedaquilineBedaquiline may increase the QTc-prolonging activities of Artemether.
BenidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Benidipine.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Artemether.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Artemether.
BepridilThe metabolism of Bepridil can be decreased when combined with Artemether.
BetaxololThe metabolism of Artemether can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Artemether can be decreased when it is combined with Bexarotene.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Artemether.
BoceprevirThe metabolism of Artemether can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Artemether can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Artemether can be decreased when it is combined with Bosentan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Artemether.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Artemether.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Artemether.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Artemether.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Artemether.
BupropionThe metabolism of Bupropion can be decreased when combined with Artemether.
BuserelinBuserelin may increase the QTc-prolonging activities of Artemether.
BuspironeThe metabolism of Buspirone can be decreased when combined with Artemether.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Artemether.
CaffeineThe metabolism of Caffeine can be decreased when combined with Artemether.
CapecitabineThe metabolism of Artemether can be decreased when combined with Capecitabine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Artemether.
CarbamazepineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Carbamazepine resulting in a loss in efficacy.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Artemether.
CarteololThe metabolism of Carteolol can be decreased when combined with Artemether.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Artemether.
CelecoxibThe metabolism of Artemether can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Artemether.
CeritinibCeritinib may increase the QTc-prolonging activities of Artemether.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Artemether.
ChloramphenicolThe metabolism of Artemether can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Artemether.
ChloroquineThe risk or severity of adverse effects can be increased when Artemether is combined with Chloroquine.
ChloroquineChloroquine may increase the QTc-prolonging activities of Artemether.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Artemether.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Artemether.
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Artemether.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Artemether.
CholecalciferolThe metabolism of Artemether can be decreased when combined with Cholecalciferol.
CilnidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Cilnidipine.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Artemether.
CimetidineThe metabolism of Artemether can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Artemether can be decreased when combined with Cinacalcet.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Artemether.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Artemether.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Artemether.
CisaprideCisapride may increase the QTc-prolonging activities of Artemether.
CitalopramCitalopram may increase the QTc-prolonging activities of Artemether.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Artemether.
ClemastineThe metabolism of Artemether can be decreased when combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Artemether.
ClobazamThe metabolism of Artemether can be decreased when combined with Clobazam.
ClomipramineThe metabolism of Artemether can be decreased when combined with Clomipramine.
ClonidineThe metabolism of Clonidine can be decreased when combined with Artemether.
ClopidogrelThe metabolism of Artemether can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Artemether can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the QTc-prolonging activities of Artemether.
ClozapineThe metabolism of Clozapine can be decreased when combined with Artemether.
CobicistatThe serum concentration of Artemether can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Artemether can be decreased when combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Artemether.
ConivaptanThe serum concentration of Artemether can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Artemether.
CrizotinibCrizotinib may increase the QTc-prolonging activities of Artemether.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Artemether.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Artemether.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Artemether.
DabrafenibThe serum concentration of Artemether can be decreased when it is combined with Dabrafenib.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Artemether.
DapsoneThe risk or severity of adverse effects can be increased when Artemether is combined with Dapsone.
DarifenacinThe metabolism of Artemether can be decreased when combined with Darifenacin.
DarodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Darodipine.
DarunavirThe serum concentration of Artemether can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Artemether.
DasatinibThe serum concentration of Artemether can be increased when it is combined with Dasatinib.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Artemether.
DeferasiroxThe serum concentration of Artemether can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Artemether.
DelavirdineThe metabolism of Artemether can be decreased when combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Artemether.
DesipramineThe metabolism of Artemether can be decreased when combined with Desipramine.
DexamethasoneThe serum concentration of Artemether can be decreased when it is combined with Dexamethasone.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Artemether.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Artemether.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Artemether.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Artemether.
DidanosineDidanosine can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Artemether.
DihydroergotamineThe metabolism of Artemether can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Artemether can be decreased when combined with Diltiazem.
DiphenhydramineThe metabolism of Artemether can be decreased when combined with Diphenhydramine.
DisopyramideDisopyramide may increase the QTc-prolonging activities of Artemether.
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Artemether.
DofetilideThe metabolism of Dofetilide can be decreased when combined with Artemether.
DofetilideDofetilide may increase the QTc-prolonging activities of Artemether.
DolasetronDolasetron may increase the QTc-prolonging activities of Artemether.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Artemether.
DomperidoneDomperidone may increase the QTc-prolonging activities of Artemether.
DonepezilThe metabolism of Donepezil can be decreased when combined with Artemether.
DopamineThe metabolism of Dopamine can be decreased when combined with Artemether.
DotarizineThe risk or severity of adverse effects can be increased when Artemether is combined with Dotarizine.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Artemether.
DoxepinDoxepin may increase the QTc-prolonging activities of Artemether.
DoxepinThe metabolism of Doxepin can be decreased when combined with Artemether.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Artemether.
DoxycyclineThe risk or severity of adverse effects can be increased when Artemether is combined with Doxycycline.
DoxycyclineThe metabolism of Artemether can be decreased when combined with Doxycycline.
DronedaroneDronedarone may increase the QTc-prolonging activities of Artemether.
DroperidolDroperidol may increase the QTc-prolonging activities of Artemether.
DuloxetineThe metabolism of Artemether can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Artemether can be decreased when it is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Artemether.
EliglustatArtemether may increase the QTc-prolonging activities of Eliglustat.
EncainideThe metabolism of Encainide can be decreased when combined with Artemether.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Artemether.
EnzalutamideThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Enzalutamide resulting in a loss in efficacy.
EperisoneThe risk or severity of adverse effects can be increased when Artemether is combined with Eperisone.
EpinastineThe metabolism of Epinastine can be decreased when combined with Artemether.
EribulinEribulin may increase the QTc-prolonging activities of Artemether.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Artemether.
ErythromycinErythromycin may increase the QTc-prolonging activities of Artemether.
EscitalopramEscitalopram may increase the QTc-prolonging activities of Artemether.
Eslicarbazepine acetateThe serum concentration of Artemether can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Artemether.
EsomeprazoleThe metabolism of Artemether can be decreased when combined with Esomeprazole.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Artemether.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Artemether.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Artemether.
EtravirineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Etravirine resulting in a loss in efficacy.
EzogabineEzogabine may increase the QTc-prolonging activities of Artemether.
FamotidineFamotidine may increase the QTc-prolonging activities of Artemether.
FelbamateFelbamate may increase the QTc-prolonging activities of Artemether.
FelodipineThe risk or severity of adverse effects can be increased when Artemether is combined with Felodipine.
FendilineThe risk or severity of adverse effects can be increased when Artemether is combined with Fendiline.
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Artemether.
FingolimodFingolimod may increase the QTc-prolonging activities of Artemether.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Artemether.
FlecainideFlecainide may increase the QTc-prolonging activities of Artemether.
FlecainideThe metabolism of Flecainide can be decreased when combined with Artemether.
FloxuridineThe metabolism of Artemether can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Artemether can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Artemether.
FluorouracilThe metabolism of Artemether can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Artemether.
FlupentixolFlupentixol may increase the QTc-prolonging activities of Artemether.
FluphenazineThe serum concentration of Fluphenazine can be increased when it is combined with Artemether.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Artemether.
FluvoxamineThe metabolism of Artemether can be decreased when combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Artemether.
FormoterolThe metabolism of Formoterol can be decreased when combined with Artemether.
FosamprenavirThe metabolism of Artemether can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Artemether can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Artemether.
FosphenytoinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Fosphenytoin resulting in a loss in efficacy.
Fusidic AcidThe serum concentration of Artemether can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Artemether is combined with Gabapentin.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Artemether.
GalantamineGalantamine may increase the QTc-prolonging activities of Artemether.
GalantamineThe metabolism of Galantamine can be decreased when combined with Artemether.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Artemether.
GemfibrozilThe metabolism of Artemether can be decreased when combined with Gemfibrozil.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Artemether.
GoserelinGoserelin may increase the QTc-prolonging activities of Artemether.
GranisetronGranisetron may increase the QTc-prolonging activities of Artemether.
GranisetronThe metabolism of Granisetron can be decreased when combined with Artemether.
HalofantrineThe risk or severity of adverse effects can be increased when Artemether is combined with Halofantrine.
HaloperidolHaloperidol may increase the QTc-prolonging activities of Artemether.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Artemether.
HalothaneThe metabolism of Halothane can be decreased when combined with Artemether.
HistrelinHistrelin may increase the QTc-prolonging activities of Artemether.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Artemether.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Artemether.
HydroxychloroquineThe risk or severity of adverse effects can be increased when Artemether is combined with Hydroxychloroquine.
HydroxychloroquineThe serum concentration of Artemether can be decreased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Artemether.
IbandronateIbandronate may increase the QTc-prolonging activities of Artemether.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Artemether.
IbutilideIbutilide may increase the QTc-prolonging activities of Artemether.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Artemether.
IdelalisibThe serum concentration of Artemether can be increased when it is combined with Idelalisib.
IloperidoneIloperidone may increase the QTc-prolonging activities of Artemether.
ImatinibThe metabolism of Artemether can be decreased when combined with Imatinib.
ImipramineThe metabolism of Artemether can be decreased when combined with Imipramine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Artemether.
IndapamideIndapamide may increase the QTc-prolonging activities of Artemether.
IndinavirThe metabolism of Artemether can be decreased when combined with Indinavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Artemether.
IrbesartanThe metabolism of Artemether can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Artemether can be decreased when combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Artemether.
IsoniazidThe metabolism of Artemether can be decreased when combined with Isoniazid.
IsradipineThe risk or severity of adverse effects can be increased when Artemether is combined with Isradipine.
IsradipineThe metabolism of Artemether can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Artemether can be decreased when combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Artemether.
IvacaftorThe serum concentration of Artemether can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Artemether.
KetoconazoleThe metabolism of Artemether can be decreased when combined with Ketoconazole.
LabetalolThe metabolism of Labetalol can be decreased when combined with Artemether.
LacidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Lacidipine.
LamotrigineThe risk or severity of adverse effects can be increased when Artemether is combined with Lamotrigine.
LapatinibLapatinib may increase the QTc-prolonging activities of Artemether.
LeflunomideThe metabolism of Artemether can be decreased when combined with Leflunomide.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Artemether.
LercanidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Lercanidipine.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Artemether.
LevodopaThe metabolism of Levodopa can be decreased when combined with Artemether.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Artemether.
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Artemether.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Artemether.
LisurideThe metabolism of Lisuride can be decreased when combined with Artemether.
LithiumLithium may increase the QTc-prolonging activities of Artemether.
LomustineThe metabolism of Lomustine can be decreased when combined with Artemether.
LoperamideThe metabolism of Loperamide can be decreased when combined with Artemether.
LopinavirLopinavir may increase the QTc-prolonging activities of Artemether.
LoratadineThe metabolism of Loratadine can be decreased when combined with Artemether.
LorcaserinThe metabolism of Artemether can be decreased when combined with Lorcaserin.
LosartanThe metabolism of Losartan can be decreased when combined with Artemether.
LovastatinThe metabolism of Artemether can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Artemether can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Artemether can be decreased when it is combined with Lumacaftor.
LumefantrineThe risk or severity of adverse effects can be increased when Artemether is combined with Lumefantrine.
LumefantrineLumefantrine may increase the QTc-prolonging activities of Artemether.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Artemether is combined with Magnesium Sulfate.
ManidipineThe risk or severity of adverse effects can be increased when Artemether is combined with Manidipine.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Artemether.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Artemether.
MefloquineThe risk or severity of adverse effects can be increased when Artemether is combined with Mefloquine.
MefloquineMefloquine may increase the QTc-prolonging activities of Artemether.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Artemether.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Artemether.
MesoridazineThe serum concentration of Mesoridazine can be increased when it is combined with Artemether.
MethadoneMethadone may increase the QTc-prolonging activities of Artemether.
MethadoneThe metabolism of Methadone can be decreased when combined with Artemether.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Artemether.
MethotrimeprazineThe serum concentration of Methotrimeprazine can be increased when it is combined with Artemether.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Artemether.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Artemether.
Methylene blueThe serum concentration of Methylene blue can be increased when it is combined with Artemether.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Artemether.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Artemether.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Artemether.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Artemether.
MetoprololThe metabolism of Artemether can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Artemether.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Artemether.
MianserinThe metabolism of Mianserin can be decreased when combined with Artemether.
MibefradilThe risk or severity of adverse effects can be increased when Artemether is combined with Mibefradil.
MifepristoneMifepristone may increase the QTc-prolonging activities of Artemether.
MinaprineThe metabolism of Minaprine can be decreased when combined with Artemether.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Artemether.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Artemether.
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Artemether.
MitotaneThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Mitotane resulting in a loss in efficacy.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Artemether.
ModafinilThe serum concentration of Artemether can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Artemether.
MoricizineThe serum concentration of Moricizine can be increased when it is combined with Artemether.
MorphineThe metabolism of Morphine can be decreased when combined with Artemether.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Artemether.
NafcillinThe serum concentration of Artemether can be decreased when it is combined with Nafcillin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Artemether.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Artemether.
NefazodoneThe metabolism of Artemether can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Artemether can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Artemether can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Artemether.
NevirapineThe serum concentration of Artemether can be decreased when it is combined with Nevirapine.
NevirapineThe metabolism of Nevirapine can be decreased when combined with Artemether.
NicardipineThe metabolism of Artemether can be decreased when combined with Nicardipine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Artemether.
NicotineThe metabolism of Nicotine can be decreased when combined with Artemether.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Artemether.
NiguldipineThe risk or severity of adverse effects can be increased when Artemether is combined with Niguldipine.
NilotinibNilotinib may increase the QTc-prolonging activities of Artemether.
NiludipineThe risk or severity of adverse effects can be increased when Artemether is combined with Niludipine.
NilvadipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Artemether is combined with Nimesulide.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Artemether.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Artemether.
NisoldipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nisoldipine.
NitrendipineThe risk or severity of adverse effects can be increased when Artemether is combined with Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Artemether.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Artemether.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Artemether.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Artemether.
OctreotideOctreotide may increase the QTc-prolonging activities of Artemether.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Artemether.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Artemether.
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Artemether.
OlaparibThe metabolism of Artemether can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Artemether.
OmeprazoleThe metabolism of Artemether can be decreased when combined with Omeprazole.
OndansetronOndansetron may increase the QTc-prolonging activities of Artemether.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Artemether.
OsimertinibThe serum concentration of Artemether can be increased when it is combined with Osimertinib.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Artemether.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Artemether.
OxytocinOxytocin may increase the QTc-prolonging activities of Artemether.
PalbociclibThe serum concentration of Artemether can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the QTc-prolonging activities of Artemether.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Artemether.
PanobinostatPanobinostat may increase the QTc-prolonging activities of Artemether.
PantoprazoleThe metabolism of Artemether can be decreased when combined with Pantoprazole.
ParoxetineThe metabolism of Paroxetine can be decreased when combined with Artemether.
PasireotidePasireotide may increase the QTc-prolonging activities of Artemether.
PazopanibPazopanib may increase the QTc-prolonging activities of Artemether.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Artemether.
Peginterferon alfa-2bThe serum concentration of Artemether can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Artemether.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Artemether.
PentobarbitalThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Pentobarbital resulting in a loss in efficacy.
PerflutrenPerflutren may increase the QTc-prolonging activities of Artemether.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Artemether.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Artemether.
PethidineThe metabolism of Pethidine can be decreased when combined with Artemether.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Artemether.
PhenforminThe metabolism of Phenformin can be decreased when combined with Artemether.
PhenobarbitalThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenobarbital resulting in a loss in efficacy.
PhenytoinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Phenytoin resulting in a loss in efficacy.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Artemether.
PimozideArtemether may increase the arrhythmogenic activities of Pimozide.
PimozidePimozide may increase the QTc-prolonging activities of Artemether.
PinaveriumThe risk or severity of adverse effects can be increased when Artemether is combined with Pinaverium.
PindololThe metabolism of Pindolol can be decreased when combined with Artemether.
PiperazineThe metabolism of Piperazine can be decreased when combined with Artemether.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Artemether.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Artemether.
PosaconazoleThe metabolism of Artemether can be decreased when combined with Posaconazole.
PregabalinThe risk or severity of adverse effects can be increased when Artemether is combined with Pregabalin.
PrenylamineThe risk or severity of adverse effects can be increased when Artemether is combined with Prenylamine.
PrimaquineThe risk or severity of adverse effects can be increased when Artemether is combined with Primaquine.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Artemether.
PrimidoneThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Primidone resulting in a loss in efficacy.
ProcainamideProcainamide may increase the QTc-prolonging activities of Artemether.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Artemether.
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Artemether.
ProguanilThe risk or severity of adverse effects can be increased when Artemether is combined with Proguanil.
PromazineThe serum concentration of Promazine can be increased when it is combined with Artemether.
PromazinePromazine may increase the QTc-prolonging activities of Artemether.
PromethazineThe serum concentration of Promethazine can be increased when it is combined with Artemether.
PromethazinePromethazine may increase the QTc-prolonging activities of Artemether.
PropafenonePropafenone may increase the QTc-prolonging activities of Artemether.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Artemether.
PropofolPropofol may increase the QTc-prolonging activities of Artemether.
PropofolThe metabolism of Propofol can be decreased when combined with Artemether.
PropranololThe metabolism of Propranolol can be decreased when combined with Artemether.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Artemether.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Artemether.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Artemether.
PyrimethamineThe risk or severity of adverse effects can be increased when Artemether is combined with Pyrimethamine.
PyrimethamineThe metabolism of Artemether can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Artemether can be increased when it is combined with Quazepam.
QuetiapineQuetiapine may increase the QTc-prolonging activities of Artemether.
QuinacrineThe risk or severity of adverse effects can be increased when Artemether is combined with Quinacrine.
QuinidineThe metabolism of Quinidine can be decreased when combined with Artemether.
QuinidineQuinidine may increase the QTc-prolonging activities of Artemether.
QuinineThe risk or severity of adverse effects can be increased when Artemether is combined with Quinine.
QuinineQuinine may increase the QTc-prolonging activities of Artemether.
RadicicolThe risk or severity of adverse effects can be increased when Artemether is combined with Radicicol.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Artemether.
RanolazineThe metabolism of Ranolazine can be decreased when combined with Artemether.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Artemether.
repinotanThe metabolism of repinotan can be decreased when combined with Artemether.
RifabutinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifabutin resulting in a loss in efficacy.
RifampicinThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifampicin resulting in a loss in efficacy.
RifapentineThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Rifapentine resulting in a loss in efficacy.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Artemether.
RisedronateThe risk or severity of adverse effects can be increased when Artemether is combined with Risedronate.
RisperidoneRisperidone may increase the QTc-prolonging activities of Artemether.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Artemether.
RitonavirThe metabolism of Artemether can be decreased when combined with Ritonavir.
RolapitantThe metabolism of Artemether can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Artemether can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Artemether.
RotigotineThe metabolism of Rotigotine can be decreased when combined with Artemether.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Artemether.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Artemether.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Artemether.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Artemether.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Artemether.
SecobarbitalThe metabolism of Artemether can be increased when combined with Secobarbital.
SertindoleThe metabolism of Sertindole can be decreased when combined with Artemether.
SertralineThe metabolism of Artemether can be decreased when combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Artemether.
SildenafilThe metabolism of Artemether can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Artemether can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Artemether can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Artemether.
SinefunginThe risk or severity of adverse effects can be increased when Artemether is combined with Sinefungin.
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Artemether.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Artemether.
SorafenibThe metabolism of Artemether can be decreased when combined with Sorafenib.
SotalolSotalol may increase the QTc-prolonging activities of Artemether.
SparteineThe metabolism of Sparteine can be decreased when combined with Artemether.
St. John's WortThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with St. John's Wort resulting in a loss in efficacy.
StiripentolThe serum concentration of Artemether can be increased when it is combined with Stiripentol.
SucralfateSucralfate can cause a decrease in the absorption of Artemether resulting in a reduced serum concentration and potentially a decrease in efficacy.
SulfadiazineThe metabolism of Artemether can be decreased when combined with Sulfadiazine.
SulfadoxineThe risk or severity of adverse effects can be increased when Artemether is combined with Sulfadoxine.
SulfamethoxazoleThe metabolism of Artemether can be decreased when combined with Sulfamethoxazole.
SulfametopyrazineThe risk or severity of adverse effects can be increased when Artemether is combined with Sulfametopyrazine.
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Artemether.
SunitinibThe metabolism of Sunitinib can be decreased when combined with Artemether.
SunitinibSunitinib may increase the QTc-prolonging activities of Artemether.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Artemether.
tafenoquineThe risk or severity of adverse effects can be increased when Artemether is combined with tafenoquine.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Artemether.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Artemether.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Artemether.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Artemether.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Artemether.
TelaprevirThe metabolism of Artemether can be decreased when combined with Telaprevir.
TelavancinTelavancin may increase the QTc-prolonging activities of Artemether.
TelithromycinTelithromycin may increase the QTc-prolonging activities of Artemether.
TerbinafineThe metabolism of Artemether can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Artemether.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Artemether.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Artemether.
TetrabenazineTetrabenazine may increase the QTc-prolonging activities of Artemether.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Artemether.
ThiethylperazineThe serum concentration of Thiethylperazine can be increased when it is combined with Artemether.
ThioridazineThioridazine may increase the QTc-prolonging activities of Artemether.
ThiotepaThe metabolism of Artemether can be decreased when combined with Thiotepa.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Artemether.
TicagrelorThe metabolism of Artemether can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Artemether can be decreased when combined with Ticlopidine.
TimololThe metabolism of Timolol can be decreased when combined with Artemether.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Artemether.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Artemether.
TizanidineTizanidine may increase the QTc-prolonging activities of Artemether.
TocilizumabThe serum concentration of Artemether can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Artemether can be decreased when combined with Tolbutamide.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Artemether is combined with Tolfenamic Acid.
TolterodineTolterodine may increase the QTc-prolonging activities of Artemether.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Artemether.
TopiramateThe metabolism of Artemether can be decreased when combined with Topiramate.
ToremifeneToremifene may increase the QTc-prolonging activities of Artemether.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Artemether.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Artemether.
TranilastThe risk or severity of adverse effects can be increased when Artemether is combined with Tranilast.
TranylcypromineThe metabolism of Artemether can be decreased when combined with Tranylcypromine.
TrazodoneTrazodone may increase the QTc-prolonging activities of Artemether.
TrazodoneThe metabolism of Trazodone can be decreased when combined with Artemether.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Artemether.
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Artemether.
TriflupromazineThe serum concentration of Triflupromazine can be increased when it is combined with Artemether.
TrimethoprimThe risk or severity of adverse effects can be increased when Artemether is combined with Trimethoprim.
TrimethoprimThe metabolism of Artemether can be decreased when combined with Trimethoprim.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Artemether.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Artemether.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Artemether.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Artemether.
Valproic AcidThe metabolism of Artemether can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Artemether can be decreased when combined with Valsartan.
VandetanibVandetanib may increase the QTc-prolonging activities of Artemether.
VardenafilVardenafil may increase the QTc-prolonging activities of Artemether.
VemurafenibArtemether may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Artemether can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Artemether is combined with Verapamil.
VerapamilThe metabolism of Artemether can be decreased when combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Artemether.
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Artemether.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Artemether.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Artemether.
VoriconazoleThe metabolism of Artemether can be decreased when combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Artemether.
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Artemether.
XylometazolineThe risk or severity of adverse effects can be increased when Artemether is combined with Xylometazoline.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Artemether.
ZafirlukastThe metabolism of Artemether can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Artemether.
ZiconotideThe risk or severity of adverse effects can be increased when Artemether is combined with Ziconotide.
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Artemether.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Artemether.
ZuclopenthixolZuclopenthixol may increase the QTc-prolonging activities of Artemether.
Food Interactions
  • Grapefruit juice may increase the toxicity of artemether and lumefantrine by inhibiting their metabolism.
  • Take with food as food increases the absorption of artemether and lumefantrine.

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US: A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. doi: 10.1007/s10928-008-9084-6. Epub 2008 Mar 19. [PubMed:18350255 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Elsherbiny DA, Asimus SA, Karlsson MO, Ashton M, Simonsson US: A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):203-17. doi: 10.1007/s10928-008-9084-6. Epub 2008 Mar 19. [PubMed:18350255 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on May 05, 2010 12:03 / Updated on August 17, 2016 12:24